Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries

49 Citationer (Scopus)

Abstract

Inhibitors of phosphodiesterases 3 and 4, the main cyclic AMP (cAMP) degrading enzymes in arteries, may have therapeutic potential in cerebrovascular disorders. We analysed the effects of such phosphodiesterases in guinea pig cerebral arteries with organ bath technique and cyclic nucleotide assays. Guinea pig and human cerebral arteries were used for phosphodiesterase assays. Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone), a phosphodiesterase 3 inhibitor, was compared to conventional phosphodiesterase 3 and 4 inhibitors. Phosphodiesterases 3 and 4 were the major contributors to total cAMP hydrolysis in the arteries examined. The phosphodiesterase 3 inhibitors additionally attenuated cyclic GMP (cGMP) hydrolysis, but relaxant responses were not dependent on an intact endothelium or on the nitric oxide-cGMP pathway. Conversely, the phosphodiesterase 4 inhibitor used was endothelium-dependent and affected by cGMP levels. This suggests that phosphodiesterase 3 inhibitors are still effective under conditions with possible dysfunctional nitric oxide-cGMP pathway, such as in ischemic stroke or cerebral vasospasm.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Pharmacology
Vol/bind489
Udgave nummer1-2
Sider (fra-til)93-100
Antal sider8
ISSN0014-2999
DOI
StatusUdgivet - 2004

Fingeraftryk

Dyk ned i forskningsemnerne om 'Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries'. Sammen danner de et unikt fingeraftryk.

Citationsformater